INSIDE INFORMATION COMMUNICATION

4 November 2025

*In accordance with the provisions of Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April on market abuse and Article 227 of Law No 6/2023 of 17 March on Securities Markets and Investment Services (the "LMVSI"), as well as other applicable regulations, Atrys Health, S.A. ("**Atrys**") hereby informs the market:*

As of 4 November, the Company, as seller, has entered into a share purchase agreement with Grupo Echevarne, S.L., as buyer, for the sale of 100% of the shares representing the share capital of Aspy Global Services, S.A.U. (the "**Transaction**").

The closing of the Transaction is subject to the fulfilment of the following conditions precedent: (i) authorisation by the National Commission on Markets and Competition (CNMC); (ii) approval of the Transaction by the Company's General Shareholders' Meeting, insofar as the perimeter of the transaction would constitute an essential asset for the purposes of Article 160(f) of the Spanish Corporations Act; and (iii) approval of the Transaction by the Company's financing entities. The Company will convene an Extraordinary General Shareholders' Meeting in the coming days, and it is estimated that closing and settlement of the Transaction may take place within the first quarter of 2026.

The purchase price of the Transaction amounts to €145 million, to be paid on the closing date of the Transaction, subject to adjustment for net financial debt. In addition, the share purchase agreement provides for additional contingent consideration of €5 million in the event of a subsequent transfer by Grupo Echevarne, S.L. to a third party within the year following closing at a price higher than that of the Transaction.

The divestment of the prevention business responds to the Atrys Group's strategy of focusing on those business areas with greater growth and profitability potential, as well as significantly reducing current levels of indebtedness. The proceeds from the sale of the prevention area will be used to reduce Financial Debt, resulting in a drastic reduction in the Net Debt / Adjusted LTM EBITDA[(1)] ratio from 3.8x to 1.1x and entailing annual financial expense savings of around €13 million.

Excluding the prevention area from the Atrys Group's perimeter, pro forma LTM[(1)] Revenue will amount to €142.5 million and the Group's Adjusted EBITDA to €28.0 million. Pro forma LTM[(1)] organic revenue growth will increase from the current +8.2% to +13.4%. It is estimated that the Transaction will result in an accounting loss of €45 million at the consolidated level.

The information disclosed has been prepared under the sole responsibility of the issuer and its directors.

Madrid, 4 November 2025

María Antonia Isach Gabaldón
Chief Executive Officer

[(1)] LTM = "Last twelve months", being the 12-month period between October 2024 and September 2025